Trial Profile
A Phase 1, Randomized, Double-Blind Study to Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ) After Intravenous Administrations in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Aug 2018
Price :
$35
*
At a glance
- Drugs Cefepime/tazobactam (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions; Pharmacokinetics
- 18 Aug 2018 New trial record